Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

FV100 as a new approach for the possible treatment of varicella-zoster virus infection

McGuigan, Christopher and Balzarini, J. 2009. FV100 as a new approach for the possible treatment of varicella-zoster virus infection. Journal of Antimicrobial Chemotherapy 64 (4) , pp. 671-673. 10.1093/jac/dkp294

Full text not available from this repository.

Abstract

FV100 is a promising new agent with extreme potency and specificity for varicella-zoster virus (VZV). It is the valyl ester pro-drug of Cf1743, the lead clinical candidate among the highly lipophilic bicyclic nucleoside analogue (BCNA) family discovered in Cardiff/Leuven. Cf1743 is unique amongst antivirals in terms of its structure and lipophilicity. It is exquisitely potent and selective for human VZV. FV100 has recently entered a randomized, controlled Phase II clinical trial for the treatment of shingles, sponsored by Inhibitex.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Pharmacy
Systems Immunity Research Institute (SIURI)
Subjects: R Medicine > RS Pharmacy and materia medica
Uncontrolled Keywords: Cf1743; BCNA; VZV; antiviral nucleoside
Publisher: Oxford University Press
ISSN: 0305-7453
Last Modified: 18 Oct 2017 13:14
URI: http://orca.cf.ac.uk/id/eprint/6637

Citation Data

Cited 14 times in Google Scholar. View in Google Scholar

Cited 14 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item